INKT Insider Trading
Insider Ownership Percentage: 22.48%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $5,427.00
MiNK Therapeutics Share Price & Price History
Current Price: $10.91
Price Change: ▲ Price Increase of +0.27 (2.54%)
As of 03/4/2026 04:59 PM ET
MiNK Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/2/2026 | Barbara Ryan | Director | Sell | 100 | $10.83 | $1,083.00 | 21,906 | |
| 2/27/2026 | Barbara Ryan | Director | Sell | 400 | $10.86 | $4,344.00 | 22,006 | |
| 10/16/2023 | Agenus Inc | Major Shareholder | Buy | 42 | $11.00 | $462.00 | 2,177,286 | |
| 10/12/2023 | Agenus Inc | Major Shareholder | Buy | 317 | $11.00 | $3,487.00 | 2,175,306 | |
| 10/4/2023 | Agenus Inc | Major Shareholder | Buy | 1,500 | $10.90 | $16,350.00 | 2,174,988 | |
| 8/28/2023 | Agenus Inc | Major Shareholder | Buy | 1,280 | $14.50 | $18,560.00 | 2,170,520 | |
| 8/24/2023 | Agenus Inc | Major Shareholder | Buy | 17,024 | $15.40 | $262,169.60 | 2,169,240 | |
| 5/10/2023 | Agenus Inc | Major Shareholder | Buy | 2,206 | $15.10 | $33,310.60 | 2,161,711 | |
| 5/5/2023 | Agenus Inc | Major Shareholder | Buy | 10,020 | $9.50 | $95,190.00 | 2,159,504 | |
| 5/5/2023 | Garo H Armen | Director | Sell | 10,000 | $9.50 | $95,000.00 | 186,640 | |
| 5/3/2023 | Agenus Inc | Major Shareholder | Buy | 12,868 | $10.80 | $138,974.40 | 2,147,337 | |
| 5/2/2023 | Garo H Armen | Director | Buy | 10,000 | $9.50 | $95,000.00 | 197,801 | |
MiNK Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/12/2026 | DRW Securities LLC | 25,677 | $0.29M | 0.0% | N/A | 0.547% |  |
| 2/12/2026 | Renaissance Technologies LLC | 10,400 | $0.12M | 0.0% | -28.8% | 0.222% |  |
| 2/9/2026 | Geode Capital Management LLC | 14,247 | $0.16M | 0.0% | +11.3% | 0.304% |  |
| 5/7/2025 | Longbow Finance SA | 16,667 | $0.14M | 0.0% | -90.0% | 0.420% |  |
| 2/13/2025 | Renaissance Technologies LLC | 101,707 | $71K | 0.0% | -4.7% | 2.566% |  |
| 2/12/2025 | Geode Capital Management LLC | 96,113 | $67K | 0.0% | -1.9% | 2.427% |  |
| 2/7/2025 | HighTower Advisors LLC | 50,676 | $35K | 0.0% | -2.0% | 1.280% |  |
| 8/9/2024 | Renaissance Technologies LLC | 127,841 | $0.12M | 0.0% | +21.5% | 0.368% |  |
| 11/14/2023 | Oracle Investment Management Inc. | 36,898 | $41K | 0.0% | -26.9% | 0.107% |  |
| 8/14/2023 | Oracle Investment Management Inc. | 50,461 | $0.11M | 0.1% | N/A | 0.146% |  |
| 8/14/2023 | Deep Track Capital LP | 324,867 | $0.68M | 0.0% | N/A | 0.941% |  |
| 8/11/2023 | Artal Group S.A. | 228,216 | $0.48M | 0.0% | -21.2% | 0.663% |  |
| 7/27/2023 | Virtu Financial LLC | 14,232 | $30K | 0.0% | N/A | 0.041% |  |
| 2/10/2023 | StoneX Group Inc. | 17,821 | $47K | 0.0% | N/A | 0.053% |  |
| 11/4/2022 | First Republic Investment Management Inc. | 81,500 | $0.17M | 0.0% | N/A | 0.243% |  |
| 2/15/2022 | Sofinnova Investments Inc. | 345,499 | $1.54M | 0.1% | N/A | 1.031% |  |
Data available starting January 2016
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Read More on MiNK Therapeutics
Today's Range
Now: $10.91
52 Week Range
Now: $10.91
Volume
1,704 shs
Average Volume
8,424 shs
Market Capitalization
$51.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.35
Who are the company insiders with the largest holdings of MiNK Therapeutics?
Who are the major institutional investors of MiNK Therapeutics?
Which major investors are selling MiNK Therapeutics stock?
During the previous quarter, INKT stock was sold by these institutional investors:
- Renaissance Technologies LLC
Which major investors are buying MiNK Therapeutics stock?
Within the last quarter, INKT stock was purchased by institutional investors including:
- DRW Securities LLC
- Geode Capital Management LLC